Page B Risk Score for Hepatocellular Carcinoma in Caucasians with Chronic Hepatitis B Under 5 Year Entecavir or Tenofovir Therapy

14 publications in the local catalog that cite this work (OpenAlex reference match; not the full global list).

1. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis 2021 Citations 364 · OpenAlex
2. Daclatasvir Plus Asunaprevir Dual Therapy for Chronic HCV Genotype 1b Infection: Results of Turkish Early Access Program 2017 Citations 297 · OpenAlex
3. An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B 2022 Citations 152 · OpenAlex
4. Residual low HDV viraemia is associated HDV RNA relapse after PEG‐IFNa‐based antiviral treatment of hepatitis delta: Results from the HIDIT‐II study 2021 Citations 152 · OpenAlex
5. MRI quantification techniques in fatty liver: the diagnostic performance of hepatic T1, T2, and stiffness measurements in relation to the proton density fat fraction 2021 Citations 152 · OpenAlex
6. Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population 2018 Citations 110 · OpenAlex
7. Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population 2018 Citations 110 · OpenAlex
8. Ten‐year follow‐up of a randomized controlled clinical trial in chronic hepatitis delta 2020 Citations 106 · OpenAlex
9. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B 2020 Citations 91 · OpenAlex
10. Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B 2021 Citations 13 · OpenAlex